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Summary: Linear ubiquitination is a post-translational protein modifi-
cation recently discovered to be crucial for innate and adaptive
immune signaling. The function of linear ubiquitin chains is regulated
at multiple levels: generation, recognition, and removal. These chains
are generated by the linear ubiquitin chain assembly complex (LU-
BAC), the only known ubiquitin E3 capable of forming the linear
ubiquitin linkage de novo. LUBAC is not only relevant for activation of
nuclear factor-jB (NF-jB) and mitogen-activated protein kinases
(MAPKs) in various signaling pathways, but importantly, it also regu-
lates cell death downstream of immune receptors capable of inducing
this response. Recognition of the linear ubiquitin linkage is specifically
mediated by certain ubiquitin receptors, which is crucial for translation
into the intended signaling outputs. LUBAC deficiency results in attenu-
ated gene activation and increased cell death, causing pathologic condi-
tions in both, mice, and humans. Removal of ubiquitin chains is
mediated by deubiquitinases (DUBs). Two of them, OTULIN and
CYLD, are constitutively associated with LUBAC. Here, we review the
current knowledge on linear ubiquitination in immune signaling path-
ways and the biochemical mechanisms as to how linear polyubiquitin
exerts its functions distinctly from those of other ubiquitin linkage
types.
Keywords: linear ubiquitination, deubiquitinases, signaling pathways, cell death,
inflammation
Introduction
Ubiquitination (also known as ubiquitylation or ubiquitiny-
lation) is a post-translational protein modification that con-
sists in the attachment of one or more ubiquitins to a target
protein. Ubiquitin is an evolutionarily highly conserved
small protein of 76 amino acids (8.6 kDa) (1). Ubiquitina-
tion is carried out by three different classes of enzymes:
ubiquitin-activating enzymes (E1s), ubiquitin-conjugating
enzymes (E2s), and ubiquitin-ligating enzymes (E3s) (2).
E1 catalyzes the activation of ubiquitin in an ATP-dependent
reaction to generate a thioester bond between the C-termi-
nal carboxyl group of ubiquitin and the catalytically active
cysteine (Cys) of the E1 enzyme. Subsequently, the activated
ubiquitin is transferred to the cysteine residue in the active
site of the E2 before the E3 mediates attachment of ubiqu-
itin to the target protein. The human genome encodes only
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two characterized E1s (3), nearly 40 E2s (4), and more than
600 E3s (5) in the ubiquitin system. According to the pres-
ence of particular domains in them, E3s are divided into
three groups: homologous to E6-AP C-terminus (HECT),
really interesting new gene (RING), and U-box E3s. In the
case of HECT E3s, ubiquitin is first transferred to the active
cysteine of the E3 and subsequently the E3 adds it to the
substrates. RING and U-box E3s instead directly mediate
transfer of ubiquitin from E2 to substrates (2).
Ubiquitin itself has seven lysine (Lys) residues that can
function as a linker to another ubiquitin (Lys6, Lys11,
Lys27, Lys29, Lys33, Lys48, and Lys63) (1) and normally
ubiquitination results in the formation of an isopeptide
bond between the carboxyl group of the C-terminal glycine
of ubiquitin and the e-amino group of lysine residue of tar-
get proteins. Yet, Kirisako et al. (6) discovered that ubiquitin
can also be conjugated to the amino-terminal methionine
(Met1) of ubiquitin itself. Therefore, there are eight differ-
ent di-ubiquitin linkages depending on which residue in
ubiquitin is linked to another ubiquitin moiety. Each type of
di-ubiquitin linkages forms a unique three-dimensional
structure. For instance, Lys6-, Lys11-, and Lys48-linked di-
ubiquitins take ‘compact’ structures with intramolecular
interfaces. In contrast, Lys63- and Met1-linked di-ubiquitins
adopt an ‘open’ structure (1). The divergent topologies of
the different linkages result in distinct biological outcomes
as they determine which ubiquitin receptors are recruited to
which linkage type and, hence, to which signaling complex.
For this reason it is important to determine the type of link-
ages present in different signaling complexes—or on indi-
vidual components of such complexes.
So far, the best characterized function of ubiquitin is its
degradative role for Lys48-linked polyubiquitin. E3 ligases
attach Lys48-linked polyubiquitin to a substrate as a degrada-
tion label and ubiquitinated substrates are subsequently sub-
jected to degradation by the proteasome (2). Nevertheless,
whereas Lys48-linked polyubiquitin serves as a signal for
destruction, the other linkage types play non-degradative
roles. Notably, Lys63- and Met1-linked (i.e. linear) polyubiq-
uitins are crucial for the regulation of diverse signaling path-
ways (1, 7). When a ubiquitin chain contains multiple types
of inter-ubiquitin linkages, it is called heterotypic or hybrid.
This diversity of ubiquitin chains confers multiple functions
which emanates from a substrate. Ubiquitination is hence a
complex post-translational modification and offers the possi-
bility to fine-tune the regulation of biological processes.
Over the past decade, Met1-linked ubiquitination has
been shown to be engaged in a wide range of immune
signaling pathways. In this review, we first explain the
molecular machinery of its production and its involvement
in multiple immune receptor signaling pathways. Subse-
quently, we focus on its regulation by specific deubiquitin-
ases (DUBs) and ubiquitin binding proteins to highlight the
mechanism by which linear ubiquitin is specifically targeted
and recognized in cells. Finally, we propose how the com-
plexity of ubiquitination, particularly the probing of linear
ubiquitin on target proteins, may be untangled.
LUBAC
The linear ubiquitin chain assembly complex (LUBAC) is
the only enzyme complex identified so far that can generate
the linear di-ubiquitin linkage de novo under native condi-
tions (8–10). LUBAC consists of two RING-between-RING
(RBR) E3s, which are heme-oxidized iron-responsive ele-
ment-binding protein 2 (IRP2) ubiquitin ligase-1 (HOIL-1)
and HOIL-1-interacting protein (HOIP), and a third compo-
nent which is the SH3 and multiple ankyrin repeat domains
protein (SHANK)-associated RBCK1 homology (RH)-
domain-interacting protein (SHARPIN) (11–13). Although
both HOIL-1 and HOIP bear an RBR domain, HOIP is the
catalytically active subunit of LUBAC, since LUBAC contain-
ing inactive HOIL-1 can still produce linear ubiquitin chains
(6). However, HOIP alone is not sufficient to create linear
ubiquitin chains as it requires at least one of the other LU-
BAC components, HOIL-1 or SHARPIN, to do so (11–13).
This implies that HOIP is self-inhibitory and that binding to
HOIL-1 or SHARPIN liberates HOIP from auto-inhibition so
that it can generate linear ubiquitin chains. HOIP interacts
with the ubiquitin-like domain (UBL) domain of HOIL-1
via its ubiquitin-associated (UBA) domain (6). HOIP has
been shown to bind to the UBL domain of SHARPIN via its
UBA domain (13). Our group and others proposed that the
nuclear protein localization 4-zinc-finger (NZF) 2 domain
of HOIP contributes to the binding to SHARPIN (11, 12),
although it appears to be dispensable according to Tokunaga
et al. (13). HOIL-1 and SHARPIN stabilize HOIP as the pro-
tein level of HOIP is reduced when either of the compo-
nents are depleted.
The C-terminus of HOIP harbors an RBR domain and a
linear ubiquitin chain-determining domain. Together, they
represent the minimal catalytic core capable of forming
Met1-linked di-ubiquitin (Met1-di-Ub) (14). Like other
members of the RBR E3 protein family, such as Parkin and
human homolog of Drosophila Ariadne (HHARI), HOIP works
as a RING/HECT hybrid E3 (15). HOIP first binds to ubiqu-
itin-conjugated E2 via its RING1 domain. Subsequently,
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ubiquitin is transferred to a catalytic center in the RING2
domain. The distal ubiquitin moiety binds to the zinc-finger
(ZF) motif in the RING2 domain of HOIP and this binding
orients the Met1 residue in the distal ubiquitin toward the
catalytic center. In the proximity of the catalytic Cys885,
histidine (His) 877 acts as the basic residue to activate the
a-amino group of Met1 as a nucleophile. Activated Met1
attacks the thioester bond which is preformed between the
C-terminus of the proximal Ub and the catalytic cysteine to
form the Met1-di-Ub linkage (14). Therefore, the specificity
for Met1-di-Ub formation by HOIP is coordinated between
its catalytic core and its interaction with the two ubiquitin
moieties to be linked.
LUBAC in TNF signaling
The prototypic signaling complex at which ubiquitination is
studied is the TNFR1 signaling complex (TNF-RSC). Unsur-
prisingly, it was therefore also the study of this complex
that led to the discovery that LUBAC forms part of signaling
complexes and that linear ubiquitination is crucial for
enabling the physiological signaling output of TNFR1 (11,
16). Binding of TNF or lymphotoxin-a (LTa) to TNFR1
results in receptor trimerization and formation of the TNF-
RSC. Upon trimerization of TNFR1, TNF receptor-associated
death domain (TRADD) and receptor-interacting protein
kinase 1 (RIPK1) are independently recruited to the intracel-
lular death domain (DD) of TNFR1 via their respective DDs.
TRADD then serves as a platform for recruitment of TNF
receptor-associated factor 2/5 (TRAF2/5), which in turn
recruits the two E3s cellular inhibitor of apoptosis 1 and 2
(cIAP1/2). Together, cIAP1 and 2 attach Lys63-, Lys11-,
and Lys48-linked polyubiquitin to RIPK1 and to themselves
(17–19). This enables recruitment of LUBAC and a complex
consisting of TAK1-binding protein 1 and 2/3 (TAB1-
TAB2/3)-transforming growth factor b-activated kinase 1
(TAK1), referred to as the TAB/TAK complex hereafter. The
recruitment of these two complexes in turn allows for the
subsequent recruitment and activation of inhibitor of jB
(IjB) kinasea (IKKa) and IKKb through the NF jB essential
modulator (NEMO) with which they form a complex (16),
hereafter referred to as IKK complex. This results in activa-
tion of canonical NF-jB and the mitogen-activated protein
kinases (MAPKs) as the gene-activatory signaling outputs of
the TNF-RSC, leading to upregulation of a plethora of pro-
survival and inflammatory genes. Recruitment of LUBAC to
the TNF-RSC depends on the presence of TRADD and TRAF2
as well as on presence and E3 ligase activity of cIAPs (16).
Once LUBAC is recruited to the TNF-RSC, it attaches linear
ubiquitin chains to RIPK1 and NEMO, thereby stabilizing
the TNF-RSC and supporting activation of NF-jB and
MAPKs as in the absence of LUBAC components cells display
reduced TNF-induced NF-jB and MAPK activation (16)
(Fig. 1).
Under certain circumstances, TNF can also induce cell
death. When the TNF-RSC, also termed complex I of TNFR1
signaling, is destabilized, a secondary cytoplasmic complex,
known as complex II, is formed (20). TNF-induced cell
death signaling emanates from complex II. Deubiquitination
of RIPK1 by the DUB cylindromatosis (CYLD) appears to be
a prerequisite for the formation of complex II, because
ubiquitinated RIPK1 protects cells from TNF-induced death
(21–23). The biochemistry of the transition from complex I
to complex II is at present not fully understood. What we
know is that RIPK1, which dissociates from complex I,
forms the core of complex II and that it recruits the Fas-
associated protein with DD (FADD) via its own DD. RIPK1-
associated FADD in turn recruits caspase-8 via its death
effector domain, resulting in activation of this apical caspase
in the apoptosis signaling pathway. Once activated, caspase-
8 cleaves and activates the BH3-only protein BID and the
downstream effectors caspase-3 and -7 which, together,
results in apoptotic death of most cells (8, 24).
When caspase-8 activity is inhibited at complex II, or
when caspase-8 or FADD are absent from it, another type of
cell death can be induced from complex II. This form of cell
death is referred to as programmed necrosis or necroptosis
and requires the concerted action of two kinases, RIPK1 and
RIPK3, together with that of a pseudokinase, mixed lineage
kinase domain-like protein (MLKL). RIPK1 and RIPK3 can
be kept from inducing necroptosis when cleaved by caspase-
8. Interestingly, their cleavage by the caspase-8/c-FLIP hete-
rodimer, which does not induce apoptosis, appears to be
required to block necroptosis (25, 26). Once caspase-8
activity is impaired, the kinase activity of RIPK1 is responsi-
ble for phosphorylation of RIPK3. RIPK3 subsequently phos-
phorylates MLKL (27). The phosphorylation of MLKL alters
its conformation to form an oligomer. MLKL oligomers have
been reported to bind to phosphatidylinositol lipids on the
plasma membrane and to insert into the membrane to form
a pore, resulting in leakage of cellular content and necrotic
death (28, 29). Thus, depending on its constitution and the
activities of its components, two different signals emanate
from complex II and, depending on which of them prevails,
either apoptotic or necroptotic cell death ensues.
Importantly, absence of LUBAC components renders cells
more sensitive to TNF- and LTa-induced apoptosis and
© 2015 The Authors. Immunological Reviews Published by John Wiley & Sons Ltd.
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necroptosis (11, 30). It is not entirely clear how LUBAC
prevents TNFR1-mediated cell death. In LUBAC-deficient
cells TNF-induced cell death indeed coincides with reduced
activation of TNF-induced NF-jB and MAPKs. However,
LUBAC deficiency leads to robust formation of complex II
which, intriguingly, is independent of its effects on gene
activation (30). Thus, it appears that linear ubiquitination
does not maintain resistance to TNF-induced cell death indi-
rectly via gene activation. Instead, it does so directly by pre-
venting complex II formation through linear ubiquitination
in complex I. The specific linear ubiquitination event(s) in
complex I, which prevent(s) formation of complex II
remain(s), however, unresolved. Independently of the
answer to this question, LUBAC and its activity are crucial
for maintaining the balance between the gene-activatory and
cell death-inducing outputs of TNF signaling.
LUBAC in innate immune signaling
The innate immune system recognizes pathogens via pattern
recognition receptors (PRRs). Microbial products, called
pathogen-associated molecular patterns (PAMPs) and danger
signals released by damaged host cells, referred to as dam-
age- (or danger-) associated molecular patterns (DAMPs),
are recognized by PRRs from immune and non-immune
cells. There are different classes of PRRs with Toll-like recep-
tors (TLRs) and C-type lectin receptors being located in the
plasma membrane or on endosomes, whereas other PRRs
such as retinoic acid-inducible gene-I (RIG-I)-like receptors
(RLR), the absent in melanoma 2 (AIM2)-like receptors
(ALRs) and the nucleotide-binding domain and leucine-rich
repeat containing (NLR) proteins, are located in the cytosol.
Activation of PRRs by PAMPs and DAMPs triggers produc-
tion of pro-inflammatory factors responsible for recruitment
and activation of immune cells (31, 32). In this way, the
PRRs elicit a first line of defense against pathogens.
TLR/IL-1R signaling
TLRs are receptors that recognize a variety of pathogens, such
as bacteria, fungi, viruses, and protists. TLR5, TLR2-TLR1,
TLR2-TLR6, and TLR11 are located in the plasma membrane,
whereas TLR3, TLR7-TLR8, TLR9, and TLR13 are on endo-
somes (33, 34). TLR4 is present on both plasma membrane
and endosomes. Stimulation of TLRs leads to their dimeriza-
tion (33, 35). Although TLR3, TLR4, TLR5, TLR9, TLR11,
and TLR13 form homodimers, TLR2 forms a heterodimer
with TLR1 or TLR6, and TLR7 does so with TLR8. After
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ligand-induced dimerization of TLRs, the adapter proteins
myeloid differentiation primary-response protein 88
(MyD88) and Toll-interleukin (IL)-1-resistance domain-con-
taining adapter protein inducing IFNb (TRIF) can be recruited
to the receptors. All TLRs aside from TLR3 engage MyD88
upon activation, while TLR3 only recruits TRIF. Interestingly,
TLR4 can recruit both MyD88 and TRIF, depending on its
localization with TLR4 on the plasma membrane activating an
MyD88-dependent pathway and TLR4, which moves to endo-
somes switching to a TRIF-dependent pathway (34).
MyD88 recruits IL-1R-associated kinase 1 (IRAK1) and
IRAK2, IRAK4, TRAF3, TRAF6, and cIAPs (36). TRAF6
attaches Lys63-linked polyubiquitin chain to cIAPs and to
itself, creating a platform to recruit the IKK and TAB/TAK
complexes, which activates NF-jB and MAPK signaling path-
ways. In the TLR3 and TLR4 pathways, engagement of TRIF
enables NF-jB and MAPK signaling pathway activation and
also production of type-I interferons (IFNs). A complex
formed by TRIF, TRADD, TRAF6, the E3 ligase Pellino-1,
and RIPK1 recruits the IKK and TAB/TAK complexes result-
ing in NF-jB and MAPK activation (37, 38), whereas a
complex composed of TRIF, TRAF3, tank-binding kinase 1
(TBK1)/IKKe results in phosphorylation of the transcription
factors interferon regulatory factor 3 (IRF3) and IRF7 and
consequent type-I IFN production (36).
LUBAC has been shown to be involved in TLR signaling.
Primary B cells or macrophages of SHARPIN-deficient mice
display impaired NF-jB activation after lipopolysaccharide
(LPS)-mediated TLR4 stimulation (12). The pro-inflamma-
tory cytokine induction in response to different TLR ligands
in macrophages from SHARPIN-deficient mice is also attenu-
ated (39). In TLR1/2 signaling, IRAK1, IRAK4, and MyD88
have been suggested as substrates of LUBAC (40). For all
other TLR signaling pathways, the targets of LUBAC have
not yet been identified. Moreover, it is also still unclear
how LUBAC is recruited to TLR signaling complexes. Thus,
the role of linear ubiquitination in TLR signaling pathways
requires further investigation.
Signaling through IL-1 receptor (IL-1R) shares the same
molecules involved in TLR4 signaling. Binding of IL-1 to IL-
1R recruits MyD88, IRAK1, IRAK4, TRAF6, and Pellino-1
with consequent recruitment of the TAB/TAK and IKK com-
plexes, allowing NF-jB and MAPK activation (41). LUBAC
depletion attenuates IL-1-mediated NF-jB and MAPK signal-
ing activation. Indeed, SHARPIN-deficient primary keratino-
cytes and MEFs show defective IL-1-mediated NF-jB and
MAPK activation (11–13). Recently, Emmerich et al. (40)
showed that linear ubiquitin chains, attached by LUBAC, are
added onto existing Lys63-linked Ub chains conjugated to
IRAK1, and possibly to IRAK4 and MyD88, in the IL-1 sig-
naling.
RLR signaling
The RLR family includes RIG-I, the melanoma differentiation-
associated gene 5 (MDA5) and the laboratory of genetics and
physiology 2 (LPG2) receptors. They are intracellular sensors
of double-stranded ribonucleic acid (dsRNA) and, as such, of
actively replicating viruses. RIG-I and MDA5 contain two cas-
pase activation and recruitment domains (CARDs) at the N-
terminus, and a regulatory domain at the C-terminus, a cen-
tral DEAD-box helicase/ATPase domain. LPG2 shares the
same domains of RIG-I and MDA5 with the exception of the
CARD. RIG-I and MDA5 sense the viral dsRNA via their heli-
case domain and recruit an adapter protein, mitochondrial
antiviral signaling protein (MAVS), via their respective CARDs
(42). Complete activation of the receptors requires the E3
ligase activity of the tripartite motif protein 25 (TRIM25)
(43). Depending on the molecules recruited to the RIG-I/
MAVS complex, two different outputs can be achieved: NF-
jB and MAPK activation via the IKK and TAB/TAK complexes
and the production of type-I IFN via phosphorylation of
IRF3/7 (44). Downstream of RIG-I, MAVS serves as a plat-
form for recruitment of TRADD, caspase-8, RIPK1, FADD,
TRAF3, and TBK1/IKKe that promotes activation of IRF3 and
IRF7 and consequent type-I IFN production (44–46). When
TRAF6 is recruited to the complex instead of TRAF3, together
with TRAF2 and TRAF5 they are responsible for recruitment
of the IKK and TAB/TAK complexes and NF-jB and MAPK
activation. However, recent findings show that TRAF6 can
also be an IRF3 activator (47).
Recently, LUBAC has been implicated in the regulation of
RIG-I signaling (47–49). Surprisingly, however, LUBAC was
reported to suppress RIG-I-mediated type-I IFN production
by inducing TRIM25 degradation and/or inhibiting the
interaction between TRIM25 and RIG-I. Consistent with
that, depletion of either HOIL-1 or HOIP enhanced RIG-I-
mediated IFN production (49). Another study suggested that
LUBAC downregulates RIG-I-mediated IFN production via
linear ubiquitination of NEMO. According to their model,
linearly ubiquitinated NEMO binds to TRAF3 and disrupts
the TRAF3-MAVS interaction, thereby reducing IFN produc-
tion. Moreover, MEFs derived from SHARPIN-deficient mice
displayed high level of type-I IFN production (48). In con-
trast with these studies, Liu et al. (47) showed that depletion
of HOIP or SHARPIN decreases vesicular stomatitis virus-
mediated IFN secretion. Therefore, the role and mechanism
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by which LUBAC controls RIG-I/MDA5 pathways is still
controversial and needs further investigation.
Inflammasome signaling
Inflammasomes comprise a family of cytosolic multi-protein
complexes that, in response to PAMPs and DAMPs, initiate
an inflammatory response via activation of caspase-1/11 and
the consequent cleavage and secretion of IL-1b and IL-18.
In addition, inflammasome activation can result in a type of
inflammatory cell death, referred to as pyroptosis, which
requires activity of caspase-1 or -11 (50, 51). Inflamma-
somes are activated by two types of cytoplasmic receptors
appertaining to the NLR and ALR families. Inflammasomes
are formed by pathogen-sensing molecules, adapter proteins
and caspase-1. The NLR sensor molecules comprise the
NOD-, LRR-, and pyrin domain-containing 1 (NLRP1),
NLRP3, NLRP6, NLRP7, NLRP12, or NOD-, LRR-, and
CARD-containing 4 (NLRC4, also known as IPAF). The NLR
sensors, except for the NLRP1, contain three domains: a C-
terminal domain including several leucine-rich repeats
(LRRs), a central nucleotide-binding domain NBD (also
referred to as NACHT), and an N-terminal effector domain,
pyrin domain (PYD) on the NLRPs, and a CARD on NLRC4
(52). In addition to these domains, NLRP1 contains a func-
tion-to-find domain that is required for its activation (53).
The LRR domain has been implicated with the recognition
of pathogens and DAMPs and auto-regulation of NLRs. Nev-
ertheless, it remains unclear whether the binding of mole-
cules from pathogens to the sensors is direct or not. The
NACHT domain is associated with oligomerization of the
sensors and has an ATPase activity. The effector domain
interacts with adapter proteins and with caspase-1 directly.
Apoptosis-associated speck-like protein containing a cas-
pase recruitment domain (ASC) is an adapter protein that
interacts with inflammasome sensors via its PYD. Following
this interaction, ASC dimerizes and, via its CARD, recruits
monomers of pro-caspase-1 that are subsequently cleaved.
Once activated, caspase-1 cleaves pro-IL-1b and pro-IL-18
into their active forms. However, recent studies imply that
ASC is dispensable for the NLRP1 inflammasome (54, 55).
NLRC4 can activate caspase-1 through its CARD without
recruiting ASC, which is indeed not required for NLRC4-
mediated pyroptosis; nevertheless, the recruitment of ASC to
the NLRC4 inflammasome is critical for processing of cas-
pase-1, IL-1b, and IL-18 (54, 55).
The ALRs include two sensors able to induce inflamma-
some formation: the AIM2 and IFNc-inducible protein 16
(IFI16). AIM2 contains a PYD and a DNA-binding HIN
domain, whereas IFI16 has one PYD and two HIN domains
for DNA binding. They are thought to directly bind to their
ligands [viral double-stranded deoxyribonucleic acid
(dsDNA)] via the DNA-binding HIN-200 domain and to
ASC via their PYD (56). Following ASC binding to the
receptors, pro-caspase-1 is recruited to the inflammasome.
Dysregulation of inflammasomes has been associated with
several auto-inflammatory disorders and autoimmunity such
as Crohn’s disease, cryopyrin-associated periodic syndromes,
vitiligo and vitiligo-associated Addison’s disease, and familial
Mediterranean fever (57). Inflammasome activation consists
of two phases: priming and activation. In the priming
phase, inflammasome components need to be expressed in
an NF-jB-dependent manner. Subsequently, a specific in-
flammasome activator triggers formation of the inflamma-
some. Both phases are also regulated at the post-translational
level. For example, ubiquitination and deubiquitination has
been reported to play an important role in the regulation of
the NLRP3 inflammasome (58–61).
Recent studies suggest that LUBAC is associated with par-
ticular inflammasomes. Specifically, SHARPIN and HOIL-1
were shown to be required for NLRP3 inflammasome activa-
tion (60, 62). Rodgers et al. (60) showed that HOIL-1-defi-
cient bone marrow-derived macrophages (BMDMs) have
reduced level of IL-1b and caspase-1 activation upon NLRP3
stimulation independently of NF-jB activation. In contrast,
HOIL-1 deficiency has a minor impact on the NLRC4 and
AIM2 inflammasomes. Moreover, ASC has been suggested as
a substrate of LUBAC. HOIL-1 is required for muramyldipep-
tide (MDP)-induced peritonitis and for LPS-induced sepsis.
SHARPIN-deficient BMDMs are defective in IL-1b secretion
and caspase-1 activation upon several inflammasome ligands,
especially upon stimulation of the NLRP3 inflammasome
(62). It therefore appears that the involvement of SHARPIN
in inflammasome activation is related to the NF-jB-mediated
priming phase. This is in contrast with another report which
concludes that regulation of the inflammasome by HOIL-1 is
NF-jB-independent (60). The role of HOIP in inflamma-
somes as the catalytic component of LUBAC still remains to
be investigated. Thus, although it appears that LUBAC plays a
role in inflammasome signaling, whether it is involved in the
priming or activation phase requires clarification.
NOD signaling
Other members of the NLR family, such as nucleotide-bind-
ing oligomerization domain 1 (NOD1) and NOD2, instead
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induce NF-jB and MAPK activation upon stimulation with
peptidoglycans derived from bacterial cell walls. NOD1 spe-
cifically recognizes D-glutamyl-meso-diaminopimelic acid
(iE-DAP) and NOD2 recognizes MDP. Stimulation of NOD1
or NOD2 leads to formation of the NOD signaling complex
(NOD-SC) that contains, aside from the respective receptor,
also RIPK2, TRAF2, XIAP, and cIAP1/2 (63). It has been
reported that cIAP1/2 and XIAP attach Lys63-linked poly-
ubiquitin chains to RIPK2 (64, 65). This mediates recruit-
ment of the IKK and TAB/TAK complexes to enable
activation of NF-jB and MAPKs. LUBAC forms part of a
NOD2-SC that forms upon NOD2 overexpression and its
recruitment to overexpressed NOD2 depends on the E3
activity of XIAP. Without LUBAC, NF-jB activation upon
NOD2 stimulation is strongly inhibited (65, 66). A substrate
of LUBAC in NOD2 signaling is RIPK2 (67).
LUBAC in adaptive immune signaling
The adaptive immune system is responsible for a second line
of defense against pathogens which is a more specific and
sustained immune response. Adaptive immunity is mediated
by T and B cells. B cells are activated via direct contact with
antigen through their B-cell receptor (BCR). Once activated,
B cells proliferate, mature into plasma cells, and secrete
antibodies. They are the principal mediator of humoral
(or antibody-mediated) immunity. Cell-mediated adaptive
immunity, in turn, is carried out by T cells with the support
of dendritic cells, macrophages, and natural killer cells (31).
The CD40/CD40L signaling pathway is crucial for effec-
tive T- and B-cell immune responses. CD40L expressed on T
cells and other cells in inflammatory conditions binds to its
receptor CD40, a member of the TNFR superfamily, on B
cells. The CD40 signaling pathway activates NF-jB signaling.
Binding of CD40L to CD40 leads to formation of a protein
complex composed of TRAFs and cIAPs that in turn recruits
the IKK and the TAB/TAK complexes to enable NF-jB and
MAPK activation (68). LUBAC forms part of the CD40 com-
plex and its recruitment depends on the E3 activity of cIAPs
(11). B cells devoid of LUBAC components have impaired
CD40-mediated NF-jB activation (11, 69). Moreover, mice
lacking HOIP activity specifically in B cells (B-HOIP Dlinear)
display defective B-cell development in the peritoneal cavity
but not in the bone marrow (70). Activation of NF-jB and
ERK by CD40, LPS, or transmembrane activator, and calcium
modulator, and cyclophilin ligand interactor (TACI) is
impaired in B cells from B-HOIP Dlinear mice. The immune
response to thymus-dependent antigens is also impaired in
B cells lacking HOIP activity. Although the target of LUBAC
in CD40 signaling has not been identified, these results indi-
cate that LUBAC activity is important for proper CD40 sig-
naling (Table 1).
Signaling via the BCR is central for the activation and
function of B cells. Unexpectedly, while HOIP is required
for BCR signaling, HOIP activity was found to be dispens-
able for BCR-mediated NF-jB activation (70). Two single-
nucleotide polymorphisms (SNPs) in the HOIP gene have an
overall frequency of 7.77% in activated B-cell like (ABC)
diffuse large B-cell lymphoma (DLBCL) patients (71). Both
SNPs are located in the UBA domain of HOIP which is
essential for HOIL-1 binding. These mutations result in
increased NF-jB activation and enhanced HOIP-HOIL-1
interaction. On the other hand, ABC cell lines treated with a
peptide that inhibits the HOIP-HOIL-1 interaction display
decreased NF-jB activation and cell viability. In support of
this, HOIP knockdown reduces NF-jB activation and cell
viability in ABC DLBCL lines (72). Moreover, the authors
Table 1. Phenotypes of mice with deficiency or mutation in linear ubiquitin chain assembly complex (LUBAC) components or in OTU
DUB with linear linkage specificity (OTULIN)
Genotype Phenotype Not affected by Partially rescued by Completely rescued by
Sharpincpdm Chronic proliferative dermatitis/multiorgan
inflammation/splenomegaly and loss of
Peyer’s patches (84, 85)
Tnfr2/ (86) Il1r1/ (58) Tnfr1/ (86)
Bid/ (58) Caspase-8+/ (86) Ripk3/; Caspase-8+/ (86)
Rag1/ (85) Ripk3/ (86, 91) Ripk3/; FaddE-KO (91)
Il-5/ (89) Mlkl/ (86)
TraddE-KO (91)
Tnf/ (11)
Tnfr1E-KO (91)
Tnfr1/ (86)
Hoip/ Lethality at E10.5/vasculature defects (30) n.d. Tnf/ up to E15.5 (30) n.d.
Tnfr1/ up to E17.5 (30)
HoipC879S Lethality at E11.5 (40) n.d. n.d. n.d.
B-HOIP Dlinear Defect in B1 development/impaired
CD40-mediated NF-jB and MAPK (70)
n.d. n.d. n.d.
Hoil-1/ No overt phenotype (13) – – –
Otulingumby Lethality at E12.5-14.5/vasculature defects (102) n.d. n.d. n.d.
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provide evidence that LUBAC is also implicated in T-cell
receptor (TCR)-mediated NF-jB activation as knockdown of
HOIP or SHARPIN decreased TCR-mediated NF-jB activa-
tion. Surprisingly, expression of inactive HOIP did not,
however, influence NF-jB activation, implying that the role
of LUBAC in TCR-mediated NF-jB activation is independent
of the E3 ligase activity of HOIP.
Cell death and sterile inflammation
Trauma and toxin exposure can cause cell death in tissues
which could be causative for sterile inflammation. Dying and
dead cells expose and release multiple proteins and sub-
stances, that are usually contained when the cells are alive,
which can attract and activate immune cells. The recognition
of PAMPs plays a vital role in the detection of dead cells,
similar to the detection of infectious agents (73). For
instance, autologous nuclear DNA and mitochondrial DNA
are recognized by innate immune cell-expressed TLR9. As
mentioned before, in addition to PAMPs, several DAMPs alert
the presence of dead cells to immune cells. They include
high mobility group box 1 protein, heat-shock proteins, IL-
33, uric acid crystals, and adenosine triphosphate/uridine
triphosphate (ATP/UTP) (74). The release of DAMPs is
thought to be a common feature of necrotic cell death (75).
DAMPs also activate PRRs that can bind to PAMPs (Fig. 2).
In contrast to necrosis, during apoptosis, cells maintain
plasma membrane integrity, and do not release intracellular
content or DAMPs until late in the process (75). Apoptotic
cells alter their membrane composition from their viable
state so that they can be recognized by phagocytes. Indeed,
the engulfment of apoptotic cells by phagocytes promotes
the secretion of anti-inflammatory chemokines and cytokines
to dampen inflammation (76). Apoptosis is thus thought to
be more immunologically inert than necrosis. However,
recent studies shed light on the active side of apoptosis with
regard to inflammation. For instance, CD95 (Fas)-induced
cell death coincides with the production of chemokines and
cytokines and to attract immune cells (77). In the case of
conditional deletion of Tak1 in the liver, which causes
inflammation-associated carcinogenesis, concurrent ablation
of caspase-8 results in reduced cell death, amelioration of
inflammation, and prevention of liver carcinogenesis (78).
Another example is the specific deletion of Ripk1 in intestinal
epithelial cells (Ripk1iEC-KO), which results in spontaneous
severe gut inflammation and lethality within 4 weeks of age
(79, 80). Conditional ablation of apoptosis through genetic
deletion of Fadd or Caspase-8, but not Ripk3, in intestinal
epithelial cells completely prevents cell death and rescues
the phenotype of Ripk1iEC-KO mice (79, 80). Deletion of Ripk1
in the epidermal keratinocytes (Ripk1E-KO) instead leads to a
skin inflammatory phenotype that is completely prevented
by genetic ablation of the two known downstream compo-
nents of necroptosis signaling, RIPK3 or MLKL, indicating
that in this case aberrant necroptosis is causative for inflam-
mation (79). Mice with specific deletion of Fadd or Caspase-8
in epidermal keratinocytes also develop severe skin inflam-
mation that is abrogated by concomitant Ripk3 deletion,
implying that increased necroptosis triggers skin inflamma-
tion (79). Therefore, exacerbated cell death, which can
either be apoptotic or necroptotic, can result in an inflam-
matory phenotype (Fig. 2).
In humans, cell death is involved in multiple human dis-
eases, such as sepsis, ischemia-reperfusion injury, liver dis-
ease, and cancer. Because cell death and inflammation can
trigger each other, exacerbated cell death further amplifies
inflammation, and vice versa, in tissues (81). Tight regulation
of cell death is therefore needed to prevent inflammatory
disease.
LUBAC deficiency in mice and humans
As discussed above, LUBAC is crucial to maintain the bal-
ance between gene-activatory and cell death signaling path-
ways upon different stimuli. Therefore, absence or
attenuation of LUBAC activity leads to aberrant signaling
output with decreased gene activation and increased cell
death. Here, we discuss the effect of deficiency of the three
different LUBAC components in mice and humans which,
depending on the component that is absent, results in devel-
opmental defects, immunosuppression, inflammation, and/
or autoimmunity.
Sharpin-deficient mice
Mice with a spontaneous deletion in the first exon of the
Sharpin gene, which results in complete absence of expression
of SHARPIN protein, develop chronic proliferative dermatitis
(referred to as cpdm) at 3–6 weeks of age (82, 83).
Increased cell death indicators, cleaved caspase-3, -7, and -
9, are detected as early as at 2 weeks of age in the epider-
mis of cpdm mice (12, 84–86). Primary keratinocytes and
MEFs from cpdm mice are more sensitive to TNF-induced
death and have a decreased capacity to activate NF-jB in
response to TNF (11–13). The skin of cpdm mice is charac-
terized by epidermal hyperplasia, hyperkeratosis and para-
keratosis and it is highly inflamed with accumulation of
© 2015 The Authors. Immunological Reviews Published by John Wiley & Sons Ltd.
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eosinophils, macrophages, and neutrophils. It has an
increased expression of type 2 cytokines, which is a feature
of type 2 inflammatory responses (87). Inflammation in
other organs such as the liver, gut, lung, and esophagus is
also observed in these mice, together with splenomegaly
and loss of Peyer’s patches (82, 88).
To understand the contribution of hematopoiesis to the
pathogenesis of cpdm mice, several genetic experiments have
been performed. Cpdm mice lacking B and T cells (cpdm;
Rag1/) still develop dermatitis, indicating that the lym-
phoid compartment is dispensable for development of the
cpdm phenotype (85). While depletion of eosinophils, either
via IL-5-neutralizing antibodies or by genetic ablation of IL-
5, effectively decreased the number of cutaneous and circu-
lating eosinophils, dermatitis was not ameliorated, demon-
strating that eosinophils do not play a vital role in the
development of the cpdm pathology (89). Also, transfer of
bone marrow cells and splenocytes from cpdm to wildtype
mice was incapable of transferring the disease (82, 86, 90).
On the other hand, cpdm skin transplantation onto nude mice
maintained the donor phenotype 3 months after transplanta-
tion (90). Together, these results point toward the cpdm phe-
notype likely being a result of a skin-intrinsic defect and
that the hematopoietic compartment is unlikely to play a
crucial role in the development of the inflammatory mani-
festations of the cpdm phenotype.
As we found increased cell death in the epidermis of cpdm
mice and that cpdm-derived keratinocytes underwent aber-
rant TNF-induced death in vitro, we ablated TNF in cpdm mice
which resulted in complete prevention of inflammation
(11). Together, this allowed us to conclude that TNF-medi-
ated cell death was responsible for the inflammatory mani-
festations of the cpdm phenotype. This conclusion was
confirmed in two recent studies, which in addition
addressed the modality of TNF-induced death that is causa-
tive for inflammation in cpdm mice. Consistent with TNF-
induced killing of keratinocytes via TNFR1 being responsible
for the observed inflammation, constitutive ablation of
TNFR1 but not TNFR2 (86), and deletion of TNFR1 specifi-
cally in the epidermal keratinocytes (Tnfr1E-KO) (91) pre-
vented development of skin lesions in cpdm mice. Address
the role necroptosis in the pathogenesis of cpdm mice, abla-
tion of RIPK3 slightly delayed the appearance of the skin
lesion in cpdm mice, whereas ablation of MLKL did not influ-
ence dermatitis in these mice. Interestingly however, co-
deletion of Ripk3 or Mlkl significantly ameliorated cell death
Find-me signals
Apoptosis
Necrosis/necroptosis/pyroptosis
Phagocytes
Lymphocytes
Granulocytes
DAMPs
IL-1/18 (pyroptosis)
Cell death-inducing stimuli
Inflammation
tissue damage
Secondary necrosis
Fig. 2. Cell death induces inflammation. Several external stimuli can trigger different types of cell death. Necrosis and pyroptosis compromise
plasma membrane integrity, which leads to the release of damage- (or danger-) associated molecular patterns (DAMPs). Although apoptotic cells
normally release limited DAMPs, they can produce cytokines and chemokines (so-called find me signals), which can also attract immune cells.
However, when apoptotic cells are not engulfed by phagocytes in a timely manner, which can occur when apoptosis induction is too massive or
too rapid, they undergo secondary necrosis, and can hence also release DAMPs. These activate inflammatory cells which in turn secrete factors
that attract and activate other types of immune cells. In summary, cell death can induce an inflammatory response which can result in tissue
damage, hence autoinflammation and possibly also autoimmunity.
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and inflammation in other organs (86, 91). The differential
effects of ablation of RIPK3 and/or MLKL on the skin phe-
notype of cpdm mice imply that RIPK3 contributes to the
cpdm skin phenotype in a manner that is independent of
MLKL-mediated necroptosis. Therefore, while RIPK3-medi-
ated MLKL-dependent necroptosis is unlikely to be the sole
driver of inflammation in the skin of cpdm mice, RIPK3-med-
iated MLKL-dependent and -independent effector mecha-
nisms appear to synergize in the development of
inflammation in other organs of cpdm mice. Caspase-8 het-
erozygosity, but not BID deficiency, significantly delayed the
onset of skin lesions in cpdm mice. The complete rescue of
the cpdm phenotype is observed with Ripk3 deletion and het-
erozygous knockout of caspase-8 (cpdm; Ripk3/; Caspase-8+/
) (86) as well as by the combination of FaddE-KO and
Ripk3/ (91) (Table 1). We can therefore conclude that
TNF-mediated cell death, mainly by apoptosis, appears to be
causative for the inflammatory manifestations of the cpdm
phenotype.
Surprisingly however, co-deletion of Ripk3 and both alleles
of the Caspase-8 gene rendered cpdm mice lethal between
embryonic day (E) 17 and 3 months of age. The reason for
the lethality of triple deficiency in SHARPIN, RIPK3, and
caspase-8 remains unresolved. In this context it is notewor-
thy to mention that expression of a kinase inactive version
of RIPK1 (Ripk1K45A) instead of wildtype RIPK1 completely
rescues the cpdm phenotype (92). It therefore appears that
the lethality of the cpdm; Ripk3/; Caspase-8/ is mediated
by an uncontrolled kinase activity of RIPK1, unleashed by
deficiency in SHARPIN when both RIPK3 and Caspase-8 are
also not present, as RIPK3/Caspase-8-double-knockout mice
do not show any such defects.
HOIP-deficient mice
Deficiency in HOIP (Hoip/) results in embryonic lethality
at E10.5 caused by defective vascularization in the yolk sac.
This is phenocopied by HOIP deficiency specifically in endo-
thelial cells (30). Cell death, characterized by positivity in
TUNEL and/or cleaved caspase-3 staining, rises in the yolk
sac of systemic and endothelial-specific HOIP-deficient
embryos prior to their death at E10.5. The exacerbated cell
death is mediated by both, TNF and LTa as genetic ablation
of TNF delayed lethality of the Hoip/ to E15.5 and that of
TNFR1 prolonged their survival until E17.5, with a signifi-
cant decrease in cell death in the yolk sac and a complete
rescue of the vascularization defects in the latter case
(Table 1). Nevertheless, Tnfr1/Hoip/ embryos do not sur-
vive after late gestation (30). The reason for this lethality is
not yet known, and it will be interesting to determine the
cause of death of these mice at E17.5. Intriguingly, cIAP1/
2-double-deficient mice are rescued by TNFR1 deficiency, at
least up until birth (93). It can therefore be concluded that
the HOIP-regulated pathway responsible for lethality of
these mice is cIAP1/2-independent.
It appears that mice expressing catalytically inactive HOIP
instead of wildtype HOIP also die at an early embryonic
stage (40, 70). However, a detailed biochemical and genetic
analysis of such mice has not been presented (Table 1).
HOIL-1-deficient mice and patients
Mice deficient for HOIL-1 are viable and do not appear to
present with any overt phenotype (94) (Table 1). Yet,
administration of TNF causes liver injury in Hoil-1/ mice.
MEFs and primary hepatocytes obtained from Hoil-1/
mice are defective in TNF-induced NF-jB activation (94).
Despite this rather unspectacular phenotype in mice, human
patients with loss-of-expression and loss-of-function muta-
tions in HOIL-1 develop chronic autoinflammation, pyo-
genic bacterial disease and muscular amylopectinosis,
resulting in their premature death during infancy. Although
fibroblasts from these patients are impaired in TNF- and IL-
1b-dependent NF-jB activation, their leukocytes are hyper-
responsive to IL-1b (95). Hence, different cell types appear
to respond differently to distinct pro-inflammatory stimuli,
which could explain the co-presence of auto-inflammation
and immunodeficiency in the patients. Interestingly, anti-
TNF treatment was capable of reducing clinical inflamma-
tion in one of the HOIL-1/ patients, in line with the effect
of TNF deletion in the cpdm mice (95).
Deubiquitinases for linear ubiquitin chains
DUBs counteract ubiquitination by removing ubiquitin from
substrates. They are also responsible for processing the
ubiquitin precursor after translation. Nearly 100 DUBs are
encoded by the human genome, and they are stratified into
five families according to their specific DUB domains. There
are ubiquitin carboxy-terminal hydrolases, ubiquitin-specific
proteases (USPs), Machado–Joseph disease protein domain
proteases, ovarian tumor proteases (OTUs), and JAB/MPN/
Mov34 metalloenzyme domain proteases (96). The function
of the DUB is determined by which ubiquitin chain they
remove. One of the well-known functions of DUBs is to res-
cue proteins from proteasomal degradation by removing
Lys48-linkages attached to them. Yet, the result of a DUB
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on non-degradative ubiquitin modifications, including on
Met1-mediated linkages, is at present still unclear. Intrigu-
ingly, the two DUBs that have so far been proposed as capa-
ble of cleaving Met1-linked ubiquitin, CYLD, and OTU DUB
with linear linkage specificity (OTULIN), have recently been
shown to occur in complex together with LUBAC as both
proteins interact with the PUB domain of HOIP (97–99).
OTULIN is a highly specific DUB for the linear ubiquitin
linkage, whereas CYLD can cleave linear Ub but also Lys63-
Ub (100, 101).
OTULIN
OTULIN, also known as FAM105B, is a member of the OTU
family and shares a similar structure to that of OTUB1
(100, 102). While the other 14 annotated OTU DUBs can-
not hydrolyze Met1-di-Ub, OTULIN exclusively cleaves
Met1-Ub (100, 102). OTULIN is approximately 100-fold
more specific for cleaving Met1-di-Ub than Lys63-di-Ub,
although Met1-Ub and Lys63-Ub are structurally quite simi-
lar as both adopt an extended conformation (100). The
specificity of OTULIN toward Met1-di-Ub is attributed to its
S1’ binding site. The binding of the proximal Ub to the S1’
site fixes it at the position where all other lysine residues in
the Ub moiety, except for Lys63, are distant from the cata-
lytic center. Importantly, Lys63 is covered by a dedicated
pocket so that OTULIN can distinguish Met1 from Lys63
despite the two of them being spatially close to each other.
The requirement of glutamate (Glu) 16 of the proximal Ub
for the cleavage activity of OTULIN suggests the presence of
Ub-mediated substrate-assisted catalysis (100).
OTULIN interacts with HOIP via its PUB-interacting motif
(PIM), which binds to the N-terminal PUB domain of HOIP.
Phosphorylation of OTULIN’s tyrosine (Tyr) 56 prevents the
binding of OTULIN to HOIP (97, 98). It is currently
unknown whether this phosphorylation plays a role in regu-
lating LUBAC activity, and it is also currently unknown which
kinase is responsible for this phosphorylation. Consistent with
a role for OTULIN in counteracting linear ubiquitination, its
overexpression was shown to delay LUBAC-mediated NF-jB
signaling and JNK activation upon TNF, whereas its inducible
knockdown was reported to increase these signaling outputs
(67, 100). Unexplained, however, is the observation that
overexpression and knockdown of OTULIN both sensitize
cells to TNF-induced cell death (100). This observation sug-
gests that an optimal level of linear ubiquitination might be
required for cell survival and that both too much or too little
could be equally detrimental.
Interestingly, gumby mice carry a mutation in the gene
encoding Otulin/Fam105b that is causative for reduced cranio-
facial vasculature from E10.5 and embryonic lethality
between E12.5-E14 (102) (Table 1). Gumby mice exhibit
abnormal vessel branching in the head and trunk, although
the major vessels appear to develop normally. Although the
cause of death of OTULIN-mutant embryos appears to be
different from that of HOIP-deficient mice, it is peculiar that
both types of mice die due to deficits in vascularization (30,
102). Yet, as OTULIN-mutant embryos die approximately
2 days later than HOIP-deficient embryos (30, 102), there
might be differences that underlie the mechanisms of death
of OTULIN- versus HOIP-mutant embryos. The observations
that OTULIN mutation negatively impacts vessel develop-
ment and that OTULIN interacts with dishevelled (DVL) 2, a
Wnt signaling adapter, suggested that linear ubiquitination
could be involved in Wnt signaling. In line with this, LU-
BAC overexpression negatively regulates canonical Wnt sig-
naling while OTULIN overexpression promoted it (102).
The molecular mechanism, however, as to how LUBAC and
OTULIN would control canonical Wnt signaling remains lar-
gely elusive.
CYLD
CYLD is a tumor suppressor belonging to the USP family of
DUBs. CYLD is thought to specifically cleave Lys63- and
Met1-linkages (101, 103, 104), although one study sug-
gested that CYLD can also cleave other di-Ub linkages
(105). A recent structural study revealed that the dual speci-
ficity is supported by its flexible binding domain to the
proximal ubiquitin. CYLD can accommodate both linkage
types in a specific manner although they are in a different
orientation (104).
Mutations in the gene encoding CYLD are causative for
familial cylindromatosis (106). Most CYLD mutations are
clustered near the catalytic USP domain at the C-terminus.
Interestingly, the USP domain of CYLD has only marginal
homology to the other members of the USP family. This is
due to a B-box domain insertion right in the center of the
USP domain (103). Loss of CYLD leads to an aberrant
increase in inflammatory signaling notably increased activa-
tion of NF-jB (107). This has also been shown to increase
the formation of inflammation-associated cancers including
colorectal, skin, and liver cancers (108–110). In addition,
loss or downregulation of CYLD has been observed in sev-
eral human cancers including of the colon, the liver (111)
and the skin (106).
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CYLD activity is regulated by cleavage and phosphoryla-
tion. CYLD plays a role in various immune signaling path-
ways and multiple proteins that are crucial for these
pathways have been identified or proposed as targets of
CYLD’s DUB activity, including TRAF2/6, RIPK1, NEMO,
TAK1, and RIG-I (107). At present, CYLD is thought to
remove Lys63-Ub from these targets proteins and to thereby
shut off signaling. It will be interesting to determine
whether CYLD may also act on Met1-Ub on these or other
targets contained in the central signaling complexes of these
immune signaling pathways. CYLD is also important for cell
death induction via TNFR1 as it has been shown to be
required for the induction of necroptosis by facilitating the
formation of complex II of TNFR1 signaling. The pro-apop-
totic complex II component caspase-8 can cleave CYLD
which results in its degradation and prevention of CYLD-
dependent necroptosis (22). In addition to proteolytic cleav-
age, CYLD activity is also negatively controlled by phosphor-
ylation. Downstream of TNFR1, CYLD has been proposed to
be phosphorylated by IKKa/b in a NEMO-dependent man-
ner and that this enables TRAF2 to be sufficiently ubiquiti-
nated to signal optimally (112).
CYLD has also been reported to act as a negative regulator
of canonical Wnt signaling by removing Lys63-chains from
DVL2 (113). CYLD levels are decreased in human tumors,
which correlates with upregulated Wnt signaling as charac-
terized by b-catenin accumulation and Axin-2 expression
(113). Consistent with this, upregulation of b-catenin is also
observed in CYLD-deficient mouse livers (109). In addition,
a mutant version of HOIP that can neither bind to OTULIN
nor CYLD is also less capable of inducing canonical Wnt sig-
naling than wildtype HOIP (99).
Linear ubiquitin-binding proteins
It recently emerged that most proteins with ubiquitin-bind-
ing domains interact specifically with particular types of Ub
linkages. Thereby certain functional units are recruited to
specific Ub chains on particular targets within immune
receptor signaling complexes. Although some types of link-
ages create structurally similar di-Ub, notably Met1-linked
and Lys63-linked di-Ub, there are a clear distinction
between them in cells. The NZF domain of TAB2 and the
ubiquitin binding in ABIN and NEMO (UBAN) motif of
NEMO have specific affinities for Lys63- and Met1-linked
di-Ub linkages, respectively (114–116). For the UBAN
motif of NEMO, this distinction is possible because it simul-
taneously interacts with sites in the proximal and distal
ubiquitin of Met1-linked di-Ub, whereas it can only interact
with one of them in Lys63-linked di-Ub (116, 117).
In the next sections, we discuss the three linear ubiquitin
binding proteins known so far to regulate immune signaling
pathways, i.e. NEMO, A20, and the A20-binding and inhibi-
tor of NF-jB-1 (ABIN-1). Importantly, the functions of
these proteins largely depend on the association with ubiqu-
itin. Disruption of their ubiquitin binding capacity in rodent
models results in pathophysiological features which are clo-
sely related to immune disorders in humans. Thus, their
preferred affinity to linear ubiquitin further highlights the
significance of linear ubiquitin in regulating immunity.
NEMO
NEMO, encoded by an X-linked gene (IKBKG) in both
humans and mice, forms the IKK complex together with the
two kinases IKKa and IKKb to activate canonical NF-jB sig-
naling (118). Mutations in the gene encoding NEMO are
associated with X-linked genetic diseases in humans, includ-
ing incontinentia pigmenti (119) and anhidrotic ectodermal
dysplasia with immunodeficiency (EDA-ID) (120). As men-
tioned above, NEMO contains a ubiquitin recognition motif,
referred to as the UBAN motif. The UBAN motif is located
at the center of the coiled coil 2 (CC2) and leucine zipper
(LZ) region (CC2-LZ or CoZi domain) at the C-terminus of
NEMO. The UBAN motif has a specific binding capacity
(Kd = 1.6 lM) for linear di-Ub compared to Lys48- and
Lys63-linked di-Ub (117). The CoZi domain dimerizes and
binds to di-Ub at a 2:1 ratio (117, 121). A point mutation
in the UBAN motif, aspartate (D) 311 to glutamine (N)
(D311N) of murine NEMO is sufficient to prevent IKK acti-
vation in NEMO-deficient cells as it is unable to bind to
Lys63- or Met1-linked polyubiquitin (117, 121). Further-
more, mutations in the UBAN domain of NEMO are linked
to EDA-ID (120, 122). Taken together, these studies support
the notion that the recognition of Met1-linked ubiquitin by
NEMO is necessary for optimal NF-jB activation.
In addition to its binding capacity to linear ubiquitin,
NEMO itself can be a substrate of LUBAC. Two ubiquitina-
tion sites, Lys285 and Lys309, have been reported to be
important for the activation of NF-jB upon LUBAC overex-
pression and IL-1 stimulation (94). Importantly, a non-
ubiquitinatable mutant of NEMO (K285R/K392R) largely
phenocopies loss of NEMO. Female mice heterozygous for
the K285R/K392R mutation exhibit TNFR1-dependent
inflammatory skin lesions and splenomegaly (123), similar
to female mice heterozygous for NEMO deficiency. In
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contrast, NEMO-K392R mutant mice display no overt phe-
notype (124). Together, these studies suggest that Lys285
of NEMO, which appears to be linearly ubiquitinated, is the
crucial ubiquitination site to regulate NF-jB signaling.
A20
A20 (also known as TNFAIP3) contains an OTU domain at
the N-terminus and seven ZF domains at the C-terminus
(125). A20 is thought to act as a DUB via its OTU domain
and, at the same time, as an E3 ligase with its zinc-finger
domains to ubiquitinate substrates with Lys48-linked poly-
ubiquitin to degrade them (126). Yet, the specificity of
A20’s DUB activity is controversial. A20 was initially
thought to serve as a suppressor of NF-jB by cleaving
Lys63-di-Ub linkages (127). However, other studies indi-
cated that A20 is only capable of cleaving Lys11- and
Lys48-linked di-Ub (105, 128). Moreover, A20 is incapable
of hydrolyzing Lys63-linked di-Ub linkages on TRAF6, but
rather targets the TRAF6-ubiquitin junction to remove all of
the ubiquitin modification en bloc (129).
A20 restricts activation of NF-jB downstream of TNFR1,
CD40, TLRs, IL-1R, and NODs (127, 130–132). Mice defi-
cient for A20 develop MyD88-dependent severe multi-organ
inflammation and cachexia and die within 2 weeks of birth
(127, 133). A20-deficient cells show TNF-induced NF-jB
hyperactivation but, counter-intuitively, also increased cell
death. Surprisingly, inactivation of A20’s DUB activity by
mutating Cys103 to alanine (A) (C103A) in the OTU
domain does not elicit spontaneous inflammation in mice
(134). The C103A mutant only marginally impacts NF-jB
activation in macrophages and dendritic cells (134). This
suggests that the DUB activity of A20 is in fact dispensable
for the negative control of NF-jB activation. This inevitably
brings up a question: which function of A20 is crucial for
the regulation of NF-jB signaling, and, thereby, inflamma-
tion?
A20 has two ubiquitin binding sites in its C-terminus,
ZF4 and ZF7, and both support the E3 ligase function of
A20 (125). ZF4 is the binding site to Lys63-linked di-Ub,
but not to Lys48- or Met1-linked di-Ub. Mutation of ZF4 in
mice does not affect the anti-inflammatory function of A20
as mice harboring this mutation develop normally (135).
ZF7, in contrast, is the binding site for Met1-linked Ub and
mediates A20 recruitment to the TNF-RSC (136). ZF7 of
A20 directly inhibits the TAK1-dependent activation of
NEMO by binding to ubiquitin chains (136–138). More-
over, this inhibition is independent of A20’s catalytic activ-
ity as a DUB (136–138). A genetic mutation in ZF7 is
known to be causative for B-cell lymphoma in humans
(136, 138). It is therefore tempting to postulate that the
interaction of ZF7 of A20 with linear ubiquitin is crucial for
the regulation of multiple immune signaling pathways. To
test this, it would be interesting to investigate the anti-
inflammatory role of A20’s ZF7 in mice with a mutation in
ZF7 that interferes with Met1-di-Ub binding, as recently
suggested by Verhelst et al. (126).
A20 also serves as an inhibitor of NLRP3 inflammasome
activation/activity although not of the AIM2 and NLRC4 in-
flammasomes (139, 140). A20 restricts NLRP3-mediated
caspase-1 activation and priming of NLRP3 and pro-IL-1b/
IL-18 by downregulating NF-jB signaling upon TLR stimu-
lation. A20 is in a complex with pro-IL-1b, caspase-1, cas-
pase-8, RIPK1, and RIPK3 (139). Lys63-linked and
unanchored ubiquitin chain appears to form part of this
complex, but the presence of Met1-linked ubiquitin chains
has not yet been addressed. A20 also plays crucial roles in
immune homeostasis in different immune cell compart-
ments. Specific ablation of A20 in B cells results in abnormal
B-cell development and differentiation. A20-deficient B cells
display hyper-responsiveness, such as enhanced proliferation
and higher expression of the B-cell activation markers,
together with increased activation of canonical NF-jB in
response to B-cell mitogens (130, 141). Mice with A20-
deficient B cells exhibit splenomegaly, plasma cell hyperpla-
sia, and autoimmunity when aged (130, 141). Myeloid-spe-
cific ablation of A20 in mice induces development of
spontaneous destructive arthritis (142). This also causes
high serum levels of inflammatory cytokines related to rheu-
matoid arthritis (RA) in humans. Although ablation of
TNFR1 signaling did not ameliorate the RA-like phenotype,
intriguingly, depletion of MyD88, and neutralization of LPS
by soluble LPS-receptor mitigated inflammation. Thus, the
TLR4-MyD88 pathway, rather than TNF-TNFR1 signaling,
turns out to be critical for development of the RA-like phe-
notype in this model (140, 142). In addition, depletion of
A20 from dendritic cells resulted in the development of
colitis (143) and systemic lupus erythematosus (SLE)-like
autoimmunity (144). Multiple SNPs in the A20 gene are
indeed associated with multiple immune diseases including
SLE in humans as well (145, 146).
ABIN-1
ABIN-1 was originally identified as an A20-interacting pro-
tein in a yeast two-hybrid screen (147). Similar to NEMO,
© 2015 The Authors. Immunological Reviews Published by John Wiley & Sons Ltd.
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ABIN-1 has a UBAN motif at its C-terminus (66). The
UBAN motif of ABIN-1 also preferentially binds Met1- over
Lys63-linked di-Ub. ABIN-1 suppresses NF-jB activation
during TNFR1 and TLR signaling by binding to NEMO and
cooperating with A20 (148). ABIN-1 restricts TNF-induced
cell death by binding to ubiquitin chains (149).
Constitutive ablation of ABIN-1 in mice causes lethality
late during embryonic development and spontaneous au-
toimmunity and inflammation in rarely born mice. This
lethality is neutralized by concomitant TNF ablation (149).
The D485N mutant of murine ABIN-1, which is equivalent
to the D311N, UBAN motif mutant of murine NEMO, loses
binding capacity to both Met1- and Lys63-linked di-Ub
(150) and fails to protect against TNF-induced cell death
(149). ABIN-1-D485N mutant mice spontaneously develop
several immune defects: splenomegaly, lymphadenopathy,
germinal center formation in the spleen, and autoimmunity.
Interestingly, these immune defects are MyD88-dependent,
as MyD88 deficiency corrects all these abnormalities (150).
Nonetheless, expression of the ABIN-1-D485N instead of
wildtype ABIN-1 does not result in embryonic lethality.
Therefore, other regions of ABIN-1, aside from its UBAN
motif, appear to contribute to its pro-survival role in TNFR1
signaling in vivo.
ABIN-1 is associated with psoriasis and systemic lupus
erythematosus in humans (151, 152). Deletion of ABIN-1
from dendritic cells disrupts the immune homeostasis and
induces splenomegaly and lymphadenopathy. ABIN-1-defi-
cient dendritic cells display hyper-activation of NF-jB and
MAPK signaling and hyper-production of IL-23 in response
to TLR ligands. Interestingly, ABIN-1 protects against TLR7
ligand-induced psoriasis by MyD88-mediated signaling in
dendritic cells (153).
Identification of novel targets of linear ubiquitination
Despite the importance to distinguish diverse inter-ubiquitin
linkage types in biological systems, it has been challenging
to pinpoint specific linkage types, including linear ubiquiti-
nation, due to their relatively low abundance and chemical
similarity in nature (154). Several attempts have been made
to develop tools to probe various types of ubiquitin linkages
in situ: (i) linkage-specific antibodies; (ii) tools to concen-
trate ubiquitinated proteins such as anti-di-glycyl lysine
antibodies and ubiquitin sensors; (iii) sensitive mass-spec-
trometric analysis; and (iv) recombinant DUBs.
First, linkage-specific antibodies can detect the presence
of specific ubiquitin linkages. These antibodies were raised
by immunization with synthetic peptides that are similar to
the specific link (94), or by phage-display methods (155).
At present, several specific Met1-di-Ub-linkage-specific anti-
bodies are commercially available. After immunoprecipitat-
ing the protein of interest, Met1-di-Ub-specific antibodies
can be used to read out the presence of Met1-linked ubiqu-
itin on the protein by Western blotting. However, to be
sure that the protein is indeed linearly ubiquitinated and to
assess to which extent this is the case, specificity of the
detected linkage has to be confirmed, a task that can be
achieved by the use of recombinant DUBs that can cleave
linear ubiquitin chains as compared to other types of Ub
linkages (see below).
Second, different tools such as anti-di-glycyl lysine anti-
bodies and ubiquitin sensors have been developed to enrich
for ubiquitinated proteins. With the exception of the Met1
inter-ubiquitin linkage, ubiquitination occurs via the e-
amino group of a lysine residue on a target protein which is
linked to the C-terminus of the incoming ubiquitin [-leu-
cine (Leu)-arginine (Arg)-Gly-Gly]. Ubiquitinated proteins
therefore possess unique footprints following tryptic digest,
which is commonly employed to process proteins for highly
sensitive proteomic analysis by mass spectrometry, in the
form of specific peptides containing the di-glycyl lysine
(Gly-Gly-e-Lys) motif with each peptide identifying a ubiq-
uitination site (156). This motif is a general feature
throughout all types of ubiquitin modification; in fact, all
types of Ub-like modifications as well which has to be kept
in mind when, for example, sumoylation or neddylation
also need to be considered. Thus, anti-diglycyl lysine (in
short, anti-GGK or anti-K-e-GG) antibodies can be used to
specifically concentrate Ub- and Ub-like-modified peptides.
For example, pools of ubiquitinated peptides can be pulled
out with the antibody after tryptic digestion, and systemic
abundance of each ubiquitin linkage type is quantitatively
measurable by mass spectrometry (157). Thereby, fold
changes in the abundance between differently treated sam-
ples can be determined. Isotope labeling methods, such as
stable isotope labeling with amino acids in cell culture (SI-
LAC) (158), allow this comparative analysis. With isotope-
labelled reference peptides absolute abundance can also be
determined which is known as absolute quantification
method (159).
Multiple ubiquitin sensors have been constructed, both for
polyubiquitins in general and for linkage-specific polyubiqui-
tins. Initially a sensor termed TUBE, which stands for tandem
repeated ubiquitin entities, was developed by tandemly com-
bining the sequence of UBA of ubiquilin 1 and human
HR23A (UBA1) (160). Based on TUBE, linkage-specific
© 2015 The Authors. Immunological Reviews Published by John Wiley & Sons Ltd.
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sensors were constructed by replacing its ubiquitin binding
sites with Ub-linkage-specific domains such as, e.g. the ZFN
of TAB2 and the UBAN motif of NEMO which detect and
enrich Lys63-linked and Met1-linked ubiquitination, respec-
tively (40, 67, 117). Employing a probe with the UBAN
motif of NEMO, combined with SILAC-based mass spectrom-
etry, RIPK2 was identified as a LUBAC target in NOD2 signal-
ing (67). Since the inactive catalytic domain of OTULIN has a
20-fold or higher affinity (Kd = 100–200 nM) toward Met1-
linked di-Ub than NEMO’s UBAN motif (Kd = 3.7 lM)
(100), this might turn out to be an even more sensitive probe
for linear ubiquitin and, thus, LUBAC substrates than the
UBAN motif of NEMO.
Even after the affinity purification, there is always an issue
with non-specificity. To address this and to confirm pulled-
down linkage types of certain ubiquitinated proteins, link-
age-specific and broad-spectrum DUBs can help to answer
the question of specificity when employed in parallel and
together on affinity-purified targets. Recently, Hospenthal
et al. (161) proposed a sophisticated DUB toolbox system,
termed UbiCRest to specifically decompose tangled ubiquitin
linkages. For linear ubiquitination analysis, OTULIN is a
potent tool, as reduction in ubiquitination on a particular
protein following treatment by OTULIN corresponds to the
amount of Met1-linked ubiquitin present on this protein
and, thereby, confirms identification of such a protein as a
target of linear ubiquitination. This can be further combined
with other DUBs, such as AMSH, as performed in the
before-mentioned study by Emmerich et al. (40), who
thereby identified the presence of heterotypic Met1- and
Lys63- linkage-containing chains on components of the
TLR/IL-1R signaling pathways.
Concluding remarks
Ubiquitination plays a crucial role in regulating innate and
adaptive immunity. Past studies focused on Lys48- and
Lys63-linked ubiquitin chains in these signaling and
revealed the importance of ubiquitination. Now, the regula-
tion of signaling by ubiquitination emerges to be more
complex as linear ubiquitination, as well as Lys11-linked
ubiquitination, have recently entered the picture. Linear
ubiquitination is now widely recognized as indispensable
for the orchestration of immune signaling, albeit always in
cooperation with other types of ubiquitination.
Linear ubiquitin in signaling is created by LUBAC and
removed by linear-ubiquitin-specific DUBs. Currently, it is
thought that this is reversed by OTULIN, and perhaps by
CYLD. Linear ubiquitin chains present in signaling com-
plexes are sensed by specific interacting proteins via their
Met1-di-Ub-binding domains. We are only beginning to
decipher the precise roles of particular linear ubiquitination
events on specific target proteins with regard to recruitment
and possibly also activation of the proteins recruited to
them. It will be exciting to fill the gaps in our knowledge
of these processes to gain a better understanding of the reg-
ulation of innate and adaptive immunity.
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